Serum sodium changes in marathon participants who use NSAIDs by Steven Whatmough (7246760) et al.
Whatmough S, et al. BMJ Open Sport Exerc Med 2018;4:e000364. doi:10.1136/bmjsem-2018-000364   1
Open access Original article
Serum sodium changes in marathon 
participants who use NSAIDs
Steven Whatmough,1 Stephen Mears,2 Courtney Kipps1
To cite: Whatmough S, 
Mears S, Kipps C.  Serum 
sodium changes in 
marathon participants who 
use NSAIDs. BMJ Open 
Sport & Exercise Medicine 
2018;4:e000364. doi:10.1136/
bmjsem-2018-000364
Accepted 12 November 2018
1Institute of Sport, Exercise 
and Health, University College 
London, London, UK
2Loughborough University, 
Loughborough, UK
Correspondence to
Dr Steven Whatmough;  steven. 
whatmough@ nhs. net
© Author(s) (or their 
employer(s)) 2018. Re-use 
permitted under CC BY-NC. No 
commercial re-use. See rights 
and permissions. Published by 
BMJ.
What are the new findings?
 ► Over the course of a marathon, serum [Na] is more 
likely to fall in participants who use an non-steroidal 
anti-inflammatory medication (NSAID) than in those 
who don’t.
How might it impact on clinical practice in the near 
future?
 ► A better understanding of the additional risks of us-
ing NSAIDs during exercise will inform future guide-
lines to make marathon running a safer activity
AbsTrACT
Introduction The primary mechanism through which the 
development of exercise-associated hyponatraemia (EAH) 
occurs is excessive fluid intake. However, many internal 
and external factors have a role in the maintenance of 
total body water and non-steroidal anti-inflammatory 
medications (NSAIDs) have been implicated as a risk factor 
for the development of EAH. This study aimed to compare 
serum sodium concentrations ([Na]) in participants taking 
an NSAID before or during a marathon (NSAID group) and 
those not taking an NSAID (control group).
Methods Participants in a large city marathon were 
recruited during race registration to participate in this 
study. Blood samples and body mass measurements took 
place on the morning of the marathon and immediately 
post marathon. Blood was analysed for [Na]. Data collected 
via questionnaires included athlete demographics, NSAID 
use and estimated fluid intake.
results We obtained a full data set for 28 participants. 
Of these 28 participants, 16 took an NSAID on the day 
of the marathon. The average serum [Na] decreased by 
2.1 mmol/L in the NSAID group, while it increased by 2.3 
mmol/L in the control group NSAID group (p=0.0039). 
Estimated fluid intake was inversely correlated with both 
post-marathon serum [Na] and ∆ serum [Na] (r=−0.532, 
p=0.004 and r=−0.405 p=0.032, respectively).
Conclusion Serum [Na] levels in participants who used 
an NSAID decreased over the course of the marathon while 
it increased in those who did not use an NSAID. Excessive 
fluid intake during a marathon was associated with a lower 
post-marathon serum [Na].
InTroduCTIon
Exercise-associated hyponatraemia (EAH) is 
a potentially life-threatening cause of collapse 
during and after endurance exercise.1 2 It is 
defined as a serum sodium concentration 
([Na]) below that of the laboratory reference 
range (commonly 135 mmol/L) during or 
up to 24 hours following prolonged physical 
activity.3
Risk factors in the development of EAH 
tend to be related to fluid balance. In most 
cases, EAH is caused by overhydration during 
exercise which can result in a haemodilution 
and subsequent decrease in blood sodium 
concentration.4 5 Non-steroidal anti-inflam-
matory medications (NSAIDs) indirectly 
potentiate the water retention effects of 
vasopressin through reduction in prosta-
glandin synthesis and subsequent reduced 
renal blood flow.6 7 Change in body mass 
can be used as a marker of hydration status 
after prolonged endurance exercise, such 
as a marathon. Participants who do not lose 
weight, or indeed gain weight, over the course 
of the marathon are likely to be overhydrated 
and are at greater risk of developing EAH.8–10 
The American College of Sports Medicine 
recommend aiming for <2% body mass loss 
during sporting events to maintain hydration 
status.11 12
Despite the well-documented medical risks 
of using NSAIDs, NSAIDs are widely avail-
able without prescription. Previous studies 
have found that between 30% and 50% of 
competitors will use NSAIDs before or during 
events.13–17 Several authors have observed 
an association between NSAID use and 
development of EAH,14 18 19 although other 
studies specifically investigating EAH risk 
factors have found no correlation between 
use of NSAIDs and EAH.7 20 21 This uncer-
tainty in the relationship between NSAIDs 
and EAH prompted the Third International 
EAH Consensus Conference to recommend 
further research in this area.3
The aim of this study was to compare the 
effect of NSAID use on changes in serum 
[Na] following a marathon. It was hypothe-
sised that participants using NSAIDs before 
or during a marathon would have a greater 
by copyright.
 o
n
 31 January 2019 by guest. Protected
http://bmjopensem.bmj.com/
BM
J O
pen Sport Exerc M
ed: first published as 10.1136/bmjsem-2018-000364 on 5 December 2018. Downloaded from 
2 Whatmough S, et al. BMJ Open Sport Exerc Med 2018;4:e000364. doi:10.1136/bmjsem-2018-000364
Open access
reduction in serum [Na] (post-marathon serum [Na] – 
pre-marathon serum [Na]) than participants who did not 
use an NSAID.
MeTHods
study setting
This study took place during a 26.2 mile city marathon 
which runs annually in late spring in the UK. The average 
daytime temperature on race-day was 6°C (3°C–10°C), 
the average humidity was 58% (31%–88%) and there was 
0.2 mm of rainfall.22 There were several drinks stations 
along the route including water in 250 mL bottles every 
mile from mile 3 to mile 25 and 380 mL sports drinks 
at miles 5, 10, 15, 19 and 23. Final instructions from the 
marathon organisers which included guidelines on safe 
drinking habits (eg, to drink according to thirst) and 
recommendations to avoid NSAID use during the mara-
thon were sent to all participants in print and were also 
available to read online.
study design
A sample size calculation was used to calculate the 
number of participants required in the study in order to 
compare the change in serum [Na] from pre-marathon 
sampling to post-marathon sampling (∆ serum [Na]) in 
participants taking NSAIDs (NSAID group) and partic-
ipants not taking NSAIDs (control group). A mean ∆ 
serum [Na] difference of 3 mmol/L was deemed signifi-
cant. The SD was set at 2 mmol/L as this value has been 
used in previous research.23 The result found a sample 
size of 10 participants per group allowed 90% statistical 
power (1 - beta) with a significance level set at 5%.
Marathon participants were approached at random 
during marathon registration, which took place over the 
4 days prior to the marathon and invited to participate in 
the study. All registered entrants in the marathon were 
eligible for our study, and we deemed that participation 
in the marathon implied that participants were fit and 
healthy. Participants under 18 years of age were ineligible 
to enter the marathon and therefore were not included 
our study. Consent for participation and blood testing was 
obtained. Participants completed a brief demographic 
questionnaire.
On the day of the marathon, immediately prior to 
starting, all participants completed a brief questionnaire 
had their body mass measured wearing race clothing and 
running shoes on a Seca 803 Clara Digital Scale, accurate 
to 0.1 kg, and had a 5 mL blood sample drawn.
After crossing the finish line, participants had their 
body mass measured using the same scales. A second 5 
mL venous blood sample was drawn, and participants 
completed a brief questionnaire documenting estimated 
fluid intake, medication use, and where appropriate, 
NSAID dose.
Data regarding intended NSAID use were collected at 
race registration and again at the start line. Questions 
regarding participants knowledge of NSAID risk and safe 
dose were asked on the post-marathon questionnaire in 
order to reduce response bias. No instructions were given 
to participants with regards to NSAID use or NSAID dose. 
Risk awareness was categorised as correct if participants 
were able to name at least one correct risk or side effect 
from any NSAID. Dose awareness was categorised as 
correct if participants knew the maximum dose of the 
NSAID they had used. Maximum daily doses of medica-
tion were obtained from the British National Formulary.24 
Doses of NSAIDs are presented relative to the maximum 
daily recommended dose.
Fluid intake was estimated from the participants recall 
of the number of water and sports drink bottles picked up 
at fluid stations over the course of the marathon. Further-
more, it was based on the assumption that all bottles were 
completely consumed.
Venous blood samples were collected from an antecu-
bital vein in a seated position into a Startstedt-Monovette 
Z-Gel vacutainer system. Blood samples were stored 
upright for 30–60 min before being centrifuged (2500 
rpm for 10 min) using a Hettich Zentrifugen Rotofix 
32. Thereafter bloods were stored upright in a cooling 
bag for transport to the laboratory for analysis. Sodium, 
potassium, urea and creatinine concentrations were 
measured in duplicate using indirect ion selective elec-
trode (Siemens ADVIA 2400, Siemens, Berlin: Germany; 
CV<1.1%).
outcome measures
The laboratory’s normal reference range for [Na] was 
133–146 mmol/L. NSAID use was a key independent vari-
able. Other variables included age, body mass change, 
estimated fluid intake, marathon time and number of 
previous marathons.
statistical analysis
Statistics were calculated using IBM SPSS V.23. Contin-
uous variables, categorical and non-parametric variables 
were compared using t-tests, χ2 tests and Mann-Whitney 
U tests, respectively. Pearson’s correlation coefficient was 
used to analyse relationships between variables. Multivar-
iate analysis, using analysis of variance, further analysed 
the dependent variable ‘change in serum [Na] with the 
independent variables ‘NSAID use’ and ‘percentage mass 
change’. Statistical significance was defined as p<0.05. 
Data were recorded as mean±SD, unless stated otherwise.
resulTs
recruitment
A total of 109 participants were recruited during mara-
thon registration. A subset of 41 participants reported 
to the research station at the start line for pre-marathon 
baseline tests. All 41 participants completed the mara-
thon and 28 participants returned for data collection 
after crossing the finish line. Therefore, a complete 
dataset for 28 participants was obtained. There were 
no significant differences in age, gender, body mass, 
number of previous marathons or finish times between 
the 28 participants who completed the study and the 13 
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Table 1 Participant demographics, body mass, fluid intake and marathon time data
Complete finish line cohort
(n=28)
NSAID group
(n=16)
Control group
(n=12) P value*
Age (years) 45±9 43±8 47±11 0.316
Male:female 21:7 10:6 11:1 0.058
Body mass (kg) 79.0±16.8 77.8±18.8 80.8±14.4 0.649
Caucasian ethnicity, n (%) 23 (82.1) 13 (81.2) 12 (100) 0.112
Number of prior marathons completed 6±13 4±10 7±16 0.532
Estimated fluid intake during the marathon (L) 1.4±1.5 1.7±1.6 1.0±1.5 0.309
Race time (min) 276.0±48.0 276.8±45.6 281.0±58.7 0.834
Absolute body mass change (kg) −1.6±1.3 −1.4±1.3 −1.9±1.2 0.376
Relative body mass change (%) −2.1±1.5 −1.9±1.6 −2.3±1.4 0.568
*P values are given for analysis between the NSAID and control groups. NSAID, non-steroidal anti-inflammatory medications.
Table 2 A comparison of athlete blood results in the non-steroidal anti-inflammatory medication (NSAID) and control groups 
[a]. These were then subdivided into those taking an NSAID the morning of the marathon (mNSAID group) [b] and those taking 
an NSAID during the marathon (dNSAID group) [c]
[a] NSAID use before or during the marathon
NSAID group (n=16) Control group (n=12) P value
Pre-marathon [Na] (mmol/L) 142.8±4.1 140.2±4.4 0.114
Post-marathon [Na] (mmol/L) 140.8±4.4 142.5±1.8 0.161
∆ [Na) (mmol/L) −2.1±5.7 2.3±4.7 0.039
[b] NSAID use the morning of the marathon
NSAID group (n=11) Control group (n=17) P value
Pre-marathon [Na] (mmol/L) 142.2±4.6 141.4±4.3 0.633
Post-marathon [Na] (mmol/L) 141.4±3.7 141.6±3.6 0.874
∆ [Na] (mmol/L) −0.8±4.7 0.2±6.3 0.639
[c] NSAID use during the marathon
NSAID group (n=8) Control group (n=20) P value
Pre-marathon [Na] (mmol/L) 144.0±2.6 140.8±4.6 0.074
Post-marathon [Na] (mmol/L) 140.9±4.9 141.8±3.0 0.566
∆ [Na] (mmol/L) −3.1±6.3 1.0±5.1 0.081
∆, Change from pre-marathon to post-marathon; [Na], Sodium concentration.
participants who did not attend the research station after 
the finish line.
nsAId use and their effect on serum biochemistry
At race registration, 50 of the 109 (45.9%) participants 
stated that they intended to use an NSAID on race day 
and/or during the marathon. At the start line, 11/28 
(39%) participants had used an NSAID on the morning 
of the marathon. Also, 8 of the 28 (29%) participants 
used an NSAID during the marathon. In total, 16 of the 
28 (57.1%) participants completing the study used an 
NSAID either before or during the marathon, or both.
Participants were grouped into those who took 
an NSAID before or during the marathon (‘NSAID 
group’) and those who did not take an NSAID (‘control 
group’). The NSAID group comprised 6 females and 10 
males. The control group (n=12) had only one female 
(table 1).
Both groups finished the marathon in similar times 
(p=0.834) and estimated consuming similar volumes 
of fluid per person (p=0.309). There was no significant 
difference in absolute or relative body mass change 
between groups (p=0.376 and 0.568, respectively) over 
the course of the marathon. There was no difference 
in either pre-marathon or post-marathon serum (Na) 
between groups (table 2). However, serum (Na) levels 
in the NSAID group decreased by an average of 1.5% 
compared with an average 1.6% increase in serum (Na) 
in the control group. No differences were seen in either 
pre-marathon or post-marathon serum potassium, urea 
or creatinine between groups; nor were changes in these 
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Table 3 Comparisons of non-steroidal anti-inflammatory medication (NSAID) knowledge in the NSAID and control group
NSAID group (n=16) Control group (n=12) P value
Correct awareness of NSAID risks, n (%) 8 (50) 5 (41.7) 0.662
Correct awareness of NSAID safe dose, n (%) 6 (37.5) 4 (33.3) 0.820
Consumed more than recommended safe limit of NSAID, n (%)* 6 (37.5) – –
*Dose exceeding the maximum safe limit for a single dose as per the British National Formulary.24
parameters over the course of the marathon significant 
(data not shown).
There was a significant difference in the change in 
serum [Na] between the NSAID and control groups 
(p=0.039, table 2). Multiple linear regression suggested 
a possible correlation between the dependent variable ∆ 
serum [Na] and the independent variables percentage 
body mass change (beta=−0.34, p=0.057) and NSAID use 
(beta=−0.35, p=0.051); however, this did not quite reach 
significance. Participants who used an NSAID during the 
marathon tended to reduce serum [Na] over the course 
of the marathon. However there was no difference in 
serum [Na] between those who used an NSAID on the 
morning of the marathon (mNSAID group) and those 
who used an NSAID during the marathon (dNSAID 
group) (table 2).
Athlete knowledge of nsAIds
Ibuprofen was the most commonly used NSAID (n=14). 
The total dose of ibuprofen taken on the day of the 
marathon ranged from 200 to 1800 mg (for reference 
the recommended maximum daily dose is 2400 mg24). 
One participant used two different NSAIDs during the 
marathon (ibuprofen and diclofenac). Reasons given 
for taking NSAIDs included treating a pre-existing 
injury (n=7), prophylactic pain management (n=6) and 
perceived improvements in performance (n=3). 37.5% 
of the participants who used an NSAID were aware of the 
safe dose and 50% were aware of at least one NSAID-re-
lated risk. There were no differences in safe NSAID dose 
knowledge and NSAID risk awareness between the two 
groups (table 3).
other risk factors for eAH
Fluid intake was expressed relative to pre-marathon 
body mass (fluid intake/body mass) and compared 
with post-marathon serum [Na] and change in serum 
[Na]. Significant correlations were found in both cases 
(R=−0.581, p=0.001 and R=−0.448, p=0.017). However, 
there was no significant differences in fluid intake/
body mass between the NSAID and control groups.
Those in whom the serum [Na] fell over the course of 
the marathon were relatively inexperienced compared 
with participants in whom the serum [Na] did not fall 
(average of 2 previous marathons vs 12 previous mara-
thons, respectively, p=0.063). There were no significant 
differences in marathon experience between the 
NSAID and control groups (table 1).
There were no other significant differences in between 
these two groups, including gender, race time, body mass 
or age. Other than NSAIDs, no participants were taking 
any regular medications.
Incidence of eAH
One of the 28 participants (3.5%) had a post-race serum 
[Na] of 130 mmol/L meeting the criteria for EAH. The 
pre-race serum [Na] was 146. This participant reported 
using 800 mg ibuprofen and estimated consuming 5 L of 
fluid during the marathon and lost only 0.3% body mass. 
The race time for this participant was 4 hours 56 min. 
The participant remained asymptomatic and reported no 
subsequent effects (personal correspondence).
Correlations of serum sodium concentration
Estimated fluid intake and body mass changes were 
inversely correlated with both post-marathon serum [Na] 
and ∆ serum [Na] (figure 1). There were no significant 
correlations between estimated fluid intake and either 
absolute body mass change (r=0.110, p=0.579) or rela-
tive body mass change (r=0.161, p=0.396). Furthermore, 
marathon time did not correlate with either absolute or 
relative body mass change (r=0.008, p=0.966 and r=0.000, 
p=0.998, respectively).
Finally, no significant correlations were identified 
between race time and ∆ serum [Na] and post-marathon 
[Na] (r=−0.257, p=0.186 and r=0.032, p=0.871, respec-
tively).
discussion
Our main findings were a high prevalence of NSAID 
use among marathon participants before or during 
the marathon. Participants who consumed an NSAID 
before or during the marathon demonstrated a signifi-
cantly greater reduction in serum [Na] over the course 
of the marathon compared with those participants 
who did not use an NSAID (table 2). Fluid intake and 
change in body mass both correlated with post-mara-
thon serum [Na] and with ∆ serum [Na] (figure 1). 
One participant met the criteria for EAH.
Prevalence of nsAId use at marathons
The marathon provides written medical guidance to 
all participants which includes specific advice on fluid 
intake and recommendations to avoid using NSAIDs 
before or during the race. Despite this, 57% of this 
small study cohort used an NSAID on marathon day.
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Figure 1 Correlations between changes in serum (Na), body mass changes and estimated fluid intake. Pearson’s correlation 
coefficient and regression analysis for the respective graphs are illustrated in the underlying table.
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Participants in this present study commonly cited 
prophylactic pain management as a reason for using 
NSAIDS, although previous research has shown that 
NSAIDs do not prevent delayed onset muscle sore-
ness (DOMS) after a marathon.13 This lack of benefit 
could be explained by the short half-life of NSAIDs.25 
The half-life of ibuprofen is only 2 hours, and there-
fore it is unlikely to exert much analgesic effect past 4 
hours, the average duration of a marathon.26 This short 
half-life may be a reason participants take more than 
one dose during a marathon, and thus consume doses 
above the recommended safe maximum. Also, 50% 
of athletes using NSAIDs were unaware of the risks of 
NSAID use, and 37.5% of NSAID users consumed doses 
greater than the recommended safe maximum.
It is important to consider the clinical significance of 
the small changes in serum [Na] observed in this study. 
A difference in 4.4 mmol/L is unlikely to be of clinical 
significance. This difference may be of greater clinical 
significance when combined with other risk factors, such 
as increased fluid intake.
The effect of nsAIds on serum sodium concentration
In the present study serum [Na] decreased by 2.1 mmol/L 
in NSAID users over the course of the marathon, while it 
increased by 2.3 mmol/L in non-NSAID users (p=0.039). 
This appears to contrast with a large cohort study of 
>400 participants which found no association between 
NSAID use and the development of EAH.7 However, it 
should be noted that the definition of NSAID use in in 
this large cohort study included use up to 7 days prior to 
the marathon and did not differentiate between NSAID 
use in the days prior to the marathon and use during the 
marathon.7
A subgroup analysis was performed on the effect 
of NSAID use prior to or during the marathon. In a 
subgroup analysis on participants in this study, serum 
[Na] fell further in participants who used an NSAID 
during the marathon (3.1 mmol/L) compared with those 
who only used an NSAID before starting the marathon 
(0.8 mmol/L)(table 2). This affect may be a consequence 
of the short half-life of NSAIDs.26 No significant correla-
tions were found between serum [Na] and the dose of 
NSAIDs used.
The NSAID group did consume 0.7 L more fluid than 
the control group. Furthermore, the NSAID group lost 
0.4% less weight than the control group. Despite both 
these differences not reaching clinical significance, this 
may present a confounder.
Fluid intake, body mass changes and serum sodium 
concentrations
Body mass change is commonly used in field-based 
studies as marker of hydration and is used as a surrogate 
measure for fluid balance during a race. Several authors 
have described inverse correlations between body mass 
change and serum [Na].7 8 21 27 28 Furthermore, studies 
have described inverse correlations between fluid intake 
and serum [Na].12 29 Our study replicated these findings, 
providing further evidence to show inverse relationships 
between serum [Na] indices and estimated fluid intake, 
and between serum [Na] and body mass change. There 
was no difference in either estimated fluid intake or body 
mass change between those who used NSAIDs and those 
who did not use NSAIDs.
Incidence of eAH
One participant met the criteria for EAH. He estimated 
that he had consumed approximately 5 L and 800 mg 
of ibuprofen before and during the marathon. His 
race time was 4 hours 56 min, slightly slower than the 
average race time of all study participants 4 hours 38 
min. Given increased fluid intake is a significant factor 
in the development of EAH; this is likely to have signifi-
cantly influenced his serum [Na] during and after the 
marathon. It is interesting to note that several other 
athletes in this study estimated that they had consumed 
similar volumes of fluid, but did not use NSAIDs, yet their 
serum [Na] were not significantly affected adding further 
weight to the possible role of NSAIDs in the development 
of EAH.
limitations and implications for future research
Participants were presumed medically fit and healthy as 
they were taking part in a marathon. As a result, uniden-
tified comorbidities may have been present. Normal 
pre-race serum [Na] reduced the likelihood that partici-
pants were truly unwell on the day of the marathon.
Fluid intake during the marathon relied on athlete 
recall which is subject to bias. To minimise this limitation, 
body mass was measured immediately before and after 
the marathon to complement fluid intake data. Data 
regarding NSAID use were also collected retrospectively. 
Furthermore, NSAID type and dose was not controlled or 
accounted for in the main analysis.
There was large dropout rate between race registration 
and the start of the marathon. In addition, 13 partici-
pants did not attend the finish line research station for 
data collection. Attempts were made to contact partic-
ipants who did not attend for post-race testing. Several 
cited difficulties locating the research station among 
busy crowds. This loss to follow-up resulted in small final 
groups and therefore accuracy of results may have been 
affected.
Although the same scales were used to measure partic-
ipants body mass, running shoes were not removed. 
Accumulation of fluid (eg, sweat) within the fabric of the 
clothes and shoes may have affected apparent post-mar-
athon body mass potentially underestimating body mass 
loss. This may offer an explanation for the lack of body 
mass changes seen in some participants.
Female gender is a known risk factor for EAH, and 
the higher proportion of females to males in the NSAID 
group than the control group may have skewed the 
results. It is possible the increased risk related to female 
gender represents an association due to volume of fluid 
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relative to females’ smaller size rather than a risk factor 
per se.
Further research is required to establish if NSAIDs 
taken post-event cause similar effects on serum sodium 
levels in the 24 hours following exercise.
ConClusIon
Fifty-seven percent of a cohort of 28 marathon partici-
pants used NSAIDS before or during a marathon despite 
cautionary advice from the marathon organisers to avoid 
their use. There was a significant reduction in serum [Na] 
over the course of the marathon in participants who used 
NSAIDS while athletes who did not use NSAIDs demon-
strated an increase in serum [Na]. Estimated fluid intake 
and changes in body mass were inversely correlated with 
both post-marathon serum [Na] and ∆ serum [Na]. Only 
half the athletes using NSAIDs were aware of the risks of 
NSAID use, and 37.5% of NSAID users consumed doses 
greater than the recommended safe maximum.
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